GERMANTOWN, Md., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming TD Cowen 45th Annual Health Care Conference, being held in Boston, MA.
TD Cowen 45th Annual Health Care Conference
Format: Corporate overview and one-on-one meetings
Date: Tuesday, March 4, 2025
Time: 3:10 pm ET
Webcast: Click here
Interested parties may access a live and recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.senseonics.com.
About Senseonics
Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense® 365 and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.
Senseonics Investor Contact
Jeremy Feffer
LifeSci Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.44 |
Daily Change: | -0.01 -3.16 |
Daily Volume: | 10,478,711 |
Market Cap: | US$360.090M |
August 06, 2025 May 15, 2025 May 08, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load